{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:23:58Z","timestamp":1787847838399,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The aim of this study was to analyze the impact on vision due to delay in presentation of patients requiring intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections, consequent to COVID-19-related travel restrictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were collected retrospectively of patients who received anti-VEGF injections during four months of the COVID-19 pandemic. Visual acuities, indication for treatment were noted along with basic demographic characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Data were analyzed for 303 eyes of 263 patients. The indication for treatment was age-related macular degeneration (AMD) in 60 eyes (19.8%), while 162 eyes (53.5%) had Diabetic Macular Edema, 71 eyes (23.4%) had Retinal Vein Occlusion and 10 eyes (3.3%) had other diagnosis. The visual acuity in the treatment na\u00efve eyes (Group A,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 168) was significantly worse (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) than those who presented for retreatment (Group B,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 135). In Group B, there was a significant decline in vision for the entire cohort (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009) and those with AMD (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.036). Those in Group B presented at a mean interval of 19.1 \u00b1 10.6 (range, 4\u201364) weeks for retreatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The COVID-19 pandemic has led to a delay in patients receiving anti-VEGF injections. The visual acuity is worse in both treatment na\u00efve as well as those requiring retreatment. This could have long-term impact on vision of patients requiring this vision preserving treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2807_20","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T05:35:03Z","timestamp":1613540103000},"page":"730-733","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown"],"prefix":"10.4103","volume":"69","author":[{"given":"Manavi D","family":"Sindal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-58-20240828","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijo.IJO_797_20","article-title":"Effect of COVID-19 related lockdown on ophthalmic practice and patient care in India: Results of a survey","volume":"68","author":"Nair","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R2-58-20240828","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4103\/ijo.IJO_1673_20","article-title":"To evaluate the effect of COVID-19 pandemic and national lockdown on patient care at a Tertiary-care ophthalmology institute","volume":"68","author":"Babu","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R3-58-20240828","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4103\/ijo.IJO_871_20","article-title":"All India ophthalmological society \u2013 Indian journal of ophthalmology consensus statement on preferred practices during the COVID-19 pandemic","volume":"68","author":"Sengupta","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R4-58-20240828","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4103\/ijo.IJO_1404_20","article-title":"Evolving consensus on managing vitreo-retina and uvea practice in post-COVID-19 pandemic era","volume":"68","author":"Gupta","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R5-58-20240828","first-page":"235","article-title":"Anti-vascular endothelial growth factor indications in ocular disease","volume":"59","author":"Cornel","year":"2015","journal-title":"Rom J Ophthalmol"},{"key":"R6-58-20240828","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","article-title":"Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic","volume":"258","author":"Korobelnik","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-58-20240828","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"R9-58-20240828","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4103\/ijo.IJO_620_16","article-title":"Delayed follow-up in patients with diabetic retinopathy in South India: Social factors and impact on disease progression","volume":"65","author":"Vengadesan","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"R10-58-20240828","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European society of retina specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R11-58-20240828","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R12-58-20240828","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.ophtha.2016.04.004","article-title":"Predictors of diabetic macular edema treatment frequency with ranibizumab during the open-label extension of the RIDE and RISE trials","volume":"123","author":"Wykoff","year":"2016","journal-title":"Ophthalmology"},{"key":"R13-58-20240828","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"R14-58-20240828","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"R15-58-20240828","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/aos.12781","article-title":"Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration","volume":"93","author":"Rasmussen","year":"2015","journal-title":"Acta Ophthalmol (Copenh"},{"key":"R16-58-20240828","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12886-018-1012-y","article-title":"Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion","volume":"19","author":"Lloyd Clark","year":"2019","journal-title":"BMC Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2807_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:40:39Z","timestamp":1787845239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2807_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2807_20","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}